因年报虚假记载、资金违规占用被罚，江苏吴中退市在即

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces the risk of being delisted due to significant violations, including failure to disclose the actual controller and inflating revenue, costs, and profits, leading to stock suspension on November 26, 2025 [1][5]. Group 1: Violations and Penalties - Jiangsu Wuzhong and related personnel failed to disclose the actual controller and falsely reported financial data from 2018 to 2023, inflating revenue by a total of 4.95 billion, 4.69 billion, 4.31 billion, and 3.77 billion respectively, which accounted for 26.46%, 26.39%, 21.26%, and 16.82% of reported revenue for those years [2][3]. - The company was fined a total of 30.5 million yuan, with the actual controller, Qian Qunshan, receiving a 10-year ban from the securities market due to severe violations [4]. Group 2: Financial Performance and Business Transition - Jiangsu Wuzhong has experienced a decline in performance since 2018, with a net profit loss of 286 million yuan in that year, and has been in a loss state for most years since, except for 2019 and 2021 [7]. - The company entered the medical aesthetics sector in 2021, which initially improved its financial performance, with a net profit of 70.48 million yuan in 2024, despite a 28.64% drop in overall revenue [8]. - However, in the first quarter of the current year, the company reported a net loss of 70.32 million yuan, indicating a reversal in its financial recovery [8].